Research Topics
| N B WattsSummaryAffiliation: University of Cincinnati Country: USA Publications
| Collaborators
|
Detail Information
Publications
Is it ethical to use placebos in osteoporosis clinical trials?Nelson B Watts
Bone Health and Osteoporosis Center, University of Cincinnati College of Medicine, 222 Piedmont Avenue, Suite 4300, Cincinnati, OH 45219, USA
Curr Rheumatol Rep 6:79-84. 2004....- Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture riskNelson B Watts
University of Cincinnati Osteoporosis Center, Cincinnati, OH, USA
J Clin Densitom 7:255-61. 2004..Although patients showing an increase in BMD had a lower fracture risk than patients showing a decrease in BMD, greater increases in BMD did not necessarily predict greater decreases in fracture risk... - Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronateNelson B Watts
University of Cincinnati, Cincinnati, Ohio 45219, USA
Osteoporos Int 14:437-41. 2003..The use of appropriate historical control data provides an approach to the assessment of fracture effects in osteoporosis trials for which placebo-controlled data are not available... - Bisphosphonate treatment of osteoporosisNelson B Watts
University of Cincinnati College of Medicine, University of Cincinnati Bone Health and Osteoporosis Center, Cincinnati, OH, USA
Clin Geriatr Med 19:395-414. 2003.... - The American College of Endocrinology and Endocrine UniversityNelson B Watts
University of Cincinnati College of Medicine, Director, University of Cincinnati Bone Health and OsteoporosisCenter, Cincinnati, OH 45219, USA
Trans Am Clin Climatol Assoc 115:333-60; discussion 360. 2004..Fellows value the educational sessions and also the unique opportunity to meet and visit with their peers. This innovative program can serve as a model for other specialties... - What is osteopenia, and what should be done about it?Nelson B Watts
University of Cincinnati College of Medicine, OH 45219, USA
Cleve Clin J Med 73:29-32. 2006 - Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMDNelson B Watts
University of Cincinnati Bone Health and Osteoporosis Center, Ohio, USA
J Bone Miner Res 20:2097-104. 2005..Change in BMD did not influence the magnitude of risedronate's effect on nonvertebral fractures; the incidence of nonvertebral fractures was equally low in treated patients whose BMD increased or decreased... - Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims databaseNelson B Watts
University of Cincinnati Bone Health and Osteoporosis Center, 222 Piedmont Ave, Suite 4300, Cincinnati, OH, 45219, USA
J Manag Care Pharm 10:142-51. 2004.... - Is it ethical to use placebos in osteoporosis clinical trials?Nelson B Watts
Bone Health and Osteoporosis Center, University of Cincinnati College of Medicine, 222 Piedmont Avenue, Suite 4300, Cincinnati, OH 45219, USA
Curr Osteoporos Rep 2:31-6. 2004.... - Fundamentals and pitfalls of bone densitometry using dual-energy X-ray absorptiometry (DXA)Nelson B Watts
University of Cincinnati Bone Health and Osteoporosis Center, 222 Piedmont Avenue, Suite 4300, Cincinnati, OH 45219, USA
Osteoporos Int 15:847-54. 2004..This paper reviews the fundamentals of positioning, scan analysis, and interpretation for central DXA and highlights some of the common pitfalls that may lead to erroneous results... - Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?N B Watts
Bone Health and Osteoporosis Center, College of Medicine, University of Cincinnati, 222 Piedmont Avenue, Suite 6300, Cincinnati, OH 45219, USA
Osteoporos Int 23:327-37. 2012..Serious adverse events of infections in denosumab subjects had heterogeneous etiology, with no clear clinical pattern to suggest a relationship to time or duration of exposure to denosumab... - Fracture risk remains reduced one year after discontinuation of risedronateN B Watts
University of Cincinnati Bone Health and Osteoporosis Center, 222 Piedmont Avenue, Suite 4300, Cincinnati, OH 45219, USA
Osteoporos Int 19:365-72. 2008..Despite these changes, the risk of new morphometric vertebral fractures remained lower in previous risedronate patients compared with previous control patients... - Long-term use of bisphosphonates in osteoporosisNelson B Watts
University of Cincinnati Bone Health and Osteoporosis Center, Cincinnati, Ohio 45219, USA
J Clin Endocrinol Metab 95:1555-65. 2010..Uncommon side effects have emerged in postapproval use. Because bisphosphonates accumulate in bone and are released for months or years after treatment is stopped, it is reasonable to consider the clinical question of how long to treat... - The Fracture Risk Assessment Tool (FRAX®): applications in clinical practiceNelson B Watts
University of Cincinnati Bone Health and Osteoporosis Center, Cincinnati, OH 45219, USA
J Womens Health (Larchmt) 20:525-31. 2011..Acceptance and clinical use of FRAX may help identify men and women at increased risk for osteoporotic fracture, but implementing the tool into clinical practice may be a challenge for busy physicians... - Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatmentNelson B Watts
University of Cincinnati, Cincinnati, Ohio 45219 4231, USA
J Bone Miner Res 24:1125-31. 2009..In conclusion, loss of FN BMD at 12 mo in postmenopausal women with osteoporosis treated with TPTD is nevertheless consistent with a good treatment response in terms of VF risk reduction... - Osteonecrosis of the jawNelson B Watts
Department of Internal Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Cincinnati College of Medicine, Cincinnati, OH, USA
South Med J 101:160-5. 2008..v. bisphosphonate therapy for cancer. Patients with osteoporosis receiving lower-dose bisphosphonate therapy do not require special precautions, but should be informed of the low risk of this complication... - Risedronate prevents new vertebral fractures in postmenopausal women at high riskNelson B Watts
University of Cincinnati, Cincinnati, Ohio 45219, USA
J Clin Endocrinol Metab 88:542-9. 2003..Significant reduction in fracture risk after 1 yr is an important benefit in patients at high risk for fracture because, without treatment, these patients are likely to sustain new fractures in the near term... - The prevalence of significant left-right differences in hip bone mineral densityR Hamdy
Osteoporosis Center, College of Medicine, East Tennessee State University and VAMC, Johnson City, TN, USA
Osteoporos Int 17:1772-80. 2006..From a public health perspective, the practice of scanning both hips could potentially identify more women with osteoporosis and may help prevent future hip fractures... - Bone quantity and quality of youths working on a farm-a pilot studyAmit Bhattacharya
Biomechanics Ergonomics Research Labs, Department of Environmental Health, University of Cincinnati College of Medicine, OH 45267 0056, USA
J Agromedicine 12:27-38. 2007..Future studies with larger samples need to be carried out to further support the findings... - Risedronate on 2 consecutive days a month reduced vertebral fracture risk at 1year compared with historical placeboNelson B Watts
Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA
J Clin Densitom 13:56-62. 2010..The use of appropriate historical control data may provide an alternative design to assess fracture effects in osteoporosis trials for which simultaneous placebo-controlled data are unavailable... - Dynamic bone quality: a noninvasive measure of bone's biomechanical property in osteoporosisAmit Bhattacharya
Department of Environmental Health, University of Cincinnati College of Medicine, Cincinnati, OH, USA
J Clin Densitom 13:228-36. 2010.... - Risk factors for the development of osteoporosis and osteoporotic fractures among older menMaria Thomas-John
Division of Immunology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45267 0563, USA
J Rheumatol 36:1947-52. 2009.... - Therapies to improve bone mineral density and reduce the risk of fracture: clinical trial resultsNelson B Watts
Department of Medicine, University of Cincinnati College of Medicine, OH, USA
J Reprod Med 47:82-92. 2002..Other strategies include nonpharmacologic interventions, such as calcium supplements, vitamin D and exercise... - Standards for performing DXA in individuals with secondary causes of osteoporosisAliya A Khan
Division of Endocrinology, McMaster University, Hamilton, Ontario, Canada, and Hanover General Hospital, PA, USA
J Clin Densitom 9:47-57. 2006..Dual-energy X-ray absorptiometry is a valuable tool in assessing skeletal health in individuals with secondary causes of osteoporosis... - Clinical challenges in osteoporosis. Case 1: screening for osteoporosis in early menopauseNelson B Watts
Emory University School of Medicine, Division of Endocrinology, Atlanta, GA, USA
Semin Arthritis Rheum 31:284-5. 2002 - Diagnosis and evaluation of patients with osteoporosisNelson B Watts
University of Cincinnati College of Medicine, Bone Health and Osteoporosis Center, 222 Piedmont Avenue, Suite 4300, Cincinnati, OH 45219, USA
South Med J 97:540-1. 2004 - Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trialRebecca D Jackson
Division of Endocrinology, Diabetes, and Metabolism, The Ohio State University, Columbus, OH 43210, USA
J Bone Miner Res 21:817-28. 2006..The fracture reduction at the hip did not differ appreciably among risk strata. These data do not support overall benefit over risk, even in women at highest risk for fracture... - Comparison of serum calcium change following thyroid and nonthyroid neck surgeryNicholas Mehta
Dept of Otolaryngology-Head and Neck Surgery, Cincinnati, Ohio 45267-0001, USA
Otolaryngol Head Neck Surg 134:901-6. 2006..Postoperative calcium monitoring should be similar following total and completion thyroidectomy due to similar rates of hypocalcemia and mean calcium drops. EBM rating: B-3b... - Hyperbilirubinemia is not a major contributing factor to altered bone mineral density in patients with chronic liver diseaseDarcey L H Smith
Division of Digestive Diseases, University of Cincinnati, Cincinnati, OH 45267-0595, USA
J Clin Densitom 9:105-13. 2006.... - Intraoperative PTH: effect of sample timing and vitamin D statusMelissa McCarty Statham
Department of Otolaryngology Head and Neck Surgery, University of Cincinnati School of Medicine, Cincinnati, OH, USA
Otolaryngol Head Neck Surg 136:946-51. 2007..To assess the effect of timing of intraoperative parathormone (iPTH) samples and 25-hydroxyvitamin D (25-OHD) status on decision-making during parathyroidectomy... - Is percutaneous vertebral augmentation (vertebroplasty) effective treatment for painful vertebral fractures?Nelson B Watts
Am J Med 114:326-8. 2003 - Position Development ConferenceLeon Lenchik
Division of Radiologic Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA
South Med J 96:724-5. 2003..A second Position Development Conference will be held in July 2003 in Cincinnati, OH. For information, visit the ISCD web site: http://www.iscd.org/... - Diagnosis and management of vertebral fractures in elderly adultsAlexandra Papaioannou
Department of Medicine, Division of Geriatric Medicine AP McMaster University, Hamilton, Ontario, Canada
Am J Med 113:220-8. 2002..There is evidence from randomized controlled trials that pharmacologic therapy can reduce the risk of future fractures by 40% to 50%. Vertebroplasty may be effective in the control of pain and in obtaining stability of the spine... - The 2002 Canadian bone densitometry recommendations: take-home messagesAliya A Khan
Division of Geriatrics, McMaster University, Hamilton, ON
CMAJ 167:1141-5. 2002 - Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trialJane A Cauley
Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA 15261, USA
JAMA 290:1729-38. 2003..In the Women's Health Initiative trial of estrogen-plus-progestin therapy, women assigned to active treatment had fewer fractures... - Bisphosphonates and osteonecrosis of the jawNelson B Watts
Ann Intern Med 145:791-2; author reply 792. 2006 - Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosisPierre D Delmas
Institut National de la Santé et de la Recherche Médicale Research Unit 403 and University Claude Bernard, Hopital Edouard Herriot, Pavillon F, 69437 Lyon Cedex 03, France
J Clin Endocrinol Metab 92:1296-304. 2007..Persistence with osteoporosis treatment is poor but is important for maximum benefit... - Recommendations for the clinical evaluation of agents for treatment of osteoporosis: consensus of an expert panel representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the Stuart L Silverman
Division of Rheumatology, Cedars Sinai Medical Center and the David Geffen School of Medicine, University of California, Los Angeles, California, USA
J Bone Miner Res 23:159-65. 2008.... - Assessment of non-vertebral fracture risk in postmenopausal womenChristian Roux
Universite Paris Descartes, Faculte de Medecine, Assistance Publique Hopitaux de Paris, Hopital Cochin, Service de Rhumatologie, Paris 75014, France
Ann Rheum Dis 66:931-5. 2007..Non-vertebral (NV) fractures are responsible for a great amount of morbidity, mortality and cost attributable to osteoporosis... - Effect of precision error on T-scores and the diagnostic classification of bone statusGary M Kiebzak
Center for Orthopaedic Research and Education, St Luke s Belmont Center, Houston, TX 77025, USA
J Clin Densitom 10:239-43. 2007..We conclude that precision influences the variability around T-scores and that this variability affects the reliability of diagnostic classification... - Bone quality: getting closer to a definitionNelson B Watts
J Bone Miner Res 17:1148-50. 2002 - Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT studyPierre D Delmas
INSERM Unit 403 and University Claude Bernard, Lyon, France
J Bone Miner Res 20:557-63. 2005..Comparison between local and central readings yielded a false-negative rate of 34%. Underdiagnosis of vertebral fracture is a worldwide problem... - Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogenSteven R Goldstein
Department of Ob Gyn, New York University Medical Center, New York, NY 10016, USA
Menopause 12:160-4. 2005..Determine the effect of raloxifene or estrogen, as compared with placebo, on the reporting of urinary incontinence in postmenopausal women participating in an osteoporosis prevention trial... - Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONECharles H Chesnut
Osteoporosis Research Group, University of Washington, Seattle, WA, USA
Curr Med Res Opin 21:391-401. 2005..As osteoporosis medications must be effective across different populations, an additional objective of BONE was to investigate and report the effect of oral ibandronate in North American and European women, as described here... - Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studiesSteven Boonen
Division of Geriatric Medicine, Center for Metabolic Bone Diseases, Catholic University of Leuven, Herestraat 49, 3000 Leuven, Belgium
Osteoporos Int 16:1291-8. 2005..Risedronate was the only agent shown to demonstrate efficacy in more than one trial. Meta-analysis showed that both alendronate and risedronate provide non-vertebral anti-fracture efficacy... - Efficacy of risedronate on clinical vertebral fractures within six monthsChristian Roux
Cochin Hospital, Rene Descartes University, Paris, France
Curr Med Res Opin 20:433-9. 2004..Risedronate has been shown to reduce the incidence of radiographically-defined vertebral fractures by approximately two-thirds within 1 year... - A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal womenIan R Reid
Department of Medicine, University of Auckland, PB 92019, Auckland, New Zealand
Arch Intern Med 164:871-9. 2004..Although many studies have assessed the effects of estrogen and raloxifene hydrochloride on bone mineral density and serum lipid concentrations, there are few direct comparative data... - Combination therapy for postmenopausal osteoporosisJuliet E Compston
Department of Medicine, Addenbrooke s Hospital, Cambridge CB2 2QQ, UK
Clin Endocrinol (Oxf) 56:565-9. 2002..Thus, the use of combination therapy for treatment of osteoporosis cannot be recommended on the basis of currently available evidence... - Review of treatment modalities for postmenopausal osteoporosisRonald C Hamdy
East Tennessee State University, Johnson City, TN 37614, USA
South Med J 98:1000-14; quiz 1015-7, 1048. 2005..Drugs on the horizon include strontium ranelate, which has been shown to reduce vertebral and nonvertebral fracture risk, and zoledronic acid, an injectable bisphosphonate that increased bone density with once-yearly administration... - Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and childrenAliya A Khan
Divisions of Endocrinology and Geriatrics, McMaster University, Hamilton, ON, Canada
J Clin Densitom 7:51-64. 2004..Previously, this group addressed the performance of densitometry in postmenopausal women. This report addresses the use of densitometry in men, premenopausal women, and children with a focus on dual-energy X-ray absorptiometry... - Application of the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD Official PositionsWilliam D Leslie
University of Manitoba, Winnipeg, Manitoba, Canada, and McGuire Veterans Affairs Medical Center, Richmond, VA, USA
J Clin Densitom 9:22-30. 2006..quot; T-scores are preferred and the WHO classification is applicable for postmenopausal women and men age 50 and older. These Official Positions, rationale and evidence are discussed in the following report... - Osteonecrosis of the jaw: balancing the benefits and risks of oral bisphosphonate treatment for osteoporosisMarjorie Jeffcoat
University of Pennsylvania School of Dental Medicine, Philadelphia, USA
Gen Dent 56:96-102; quiz 103-4, 111-2. 2008..The low risk of ONJ with oral bisphosphonates should be balanced against the benefits of osteoporosis therapy... - Lessons from the Women's Health InitiativeNelson B Watts
South Med J 95:952-5. 2002 - Position statements of the International Society for Clinical Densitometry: methodologyEdward S Leib
J Clin Densitom 5:S5-10. 2002..Details of the methodology used at the conference are discussed. The following papers explain the results of the discussions and describe the official ISCD positions... - Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacyR Graham G Russell
The Oxford University Institute of Musculoskeletal Sciences, The Botnar Research Centre, Nuffield Department of Orthopaedic Surgery, Nuffield Orthopaedic Centre, Headington, Oxford, United Kingdom
Ann N Y Acad Sci 1117:209-57. 2007..As we approach the 40th anniversary of the discovery of their biological effects, there remain further opportunities for using their properties for medical purposes... - Efficacy of teriparatide and alendronate on nonvertebral fracturesNelson B Watts
J Clin Endocrinol Metab 88:1402-3; author reply 1403. 2003 - Executive summary International Society for Clinical Densitometry position development conference Denver, Colorado July 20-22, 2001Leon Lenchik
J Clin Densitom 5:S1-3. 2002..The ISCD is a not-for-profit multidisciplinary society whose main mission is to promote quality in the performance and interpretation of bone densitometry examinations... - Type 2 diabetes, thiazolidinediones: bad to the bone?Nelson B Watts
J Clin Endocrinol Metab 91:3276-8. 2006 - Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trialGlenn D Braunstein
Department of Medicine, Cedars Sinai Medical Center, Los Angeles, Calif, 90048, USA
Arch Intern Med 165:1582-9. 2005..Oophorectomy reduces serum testosterone levels. We studied the efficacy and safety of transdermal testosterone in treating hypoactive sexual desire disorder in surgically menopausal women... - Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosteroneJohn K Amory
Department of Medicine, Veterans Affairs-Puget Sound Health Care System, Seattle, WA 98195, USA
J Clin Endocrinol Metab 89:503-10. 2004..These findings have important implications for the prevention and treatment of osteoporosis in older men with low T levels... - Prior oral contraception and postmenopausal fracture: a Women's Health Initiative observational cohort studyDavid Barad
Obstetrics and Gynecology and Women s Health, Department of Epidemiology and Social Medicine, Albert Einstein College of Medicine, Bronx, New York 10021, USA
Fertil Steril 84:374-83. 2005..To test for the possible association of past oral contraceptive (OC) use and incident fracture after menopause... - Official positions of the international society for clinical densitometryE Michael Lewiecki
New Mexico Clinical Research and Osteoporosis Center, Albuquerque, New Mexico 87106, USA
J Clin Endocrinol Metab 89:3651-5. 2004..Recommendations that are accepted become the Official Positions of the ISCD. This Special Report summarizes the methodology of the ISCD Position Development Conferences and presents selected Official Positions of general interest...